Efficacy of a New Compound Containing Cimicifuga Racemosa on Menopausal Symptoms in Women with Breast Cancer

Abstract

The Hormone Replacement Therapy (HRT) is the "first-line therapy" for women with moderate / severe menopausal symptoms (hot flashes, profuse sweating, insomnia, osteoporosis). However, when the symptomatology is lighter or there are contraindications to HRT (breast disease, cardiovascular disease, thrombophilic diathesis, smoke, etc), woman can benefit from some preparations such as phytoestrogens and Cimicifuga racemosa. At present there are insufficient data regarding the efficacy and safety of phytoestrogens in women with breast cancer: because this tumour disease is hormone-dependent, phytoestrogens should be considered contraindicated in patients survived to the disease. Our study assessed both the effectiveness of a new compound containing Cimicifuga racemosa, Agnus-Castus, Ginger, Hyaluronic acid and Zinc on the neurovegetative menopausal symptoms (hot flashes, profuse sweating, insomnia) and its safe use in patients with breast cancer. The results have shown that this compound is an excellent alternative to estrogen treatment of menopausal neurovegetative symptoms, even for patients with breast cancer who cannot take HRT or phytoestrogens.